Ultimately, the management goal is not for patients with relapsed/refractory disease to live with chronic Hodgkin lymphoma while receiving immune checkpoint blockade therapy, but rather to cure more patients with first- or second-line therapy.
Anita Kumar, MD
Advertisement
Articles by Anita Kumar, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
2
Precision Medicine and the “Slow Death” of Transplant in Lymphoma
3
TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i
4
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
5